424 related articles for article (PubMed ID: 30355736)
1. Identification of two principal amyloid-driving segments in variable domains of Ig light chains in systemic light-chain amyloidosis.
Brumshtein B; Esswein SR; Sawaya MR; Rosenberg G; Ly AT; Landau M; Eisenberg DS
J Biol Chem; 2018 Dec; 293(51):19659-19671. PubMed ID: 30355736
[TBL] [Abstract][Full Text] [Related]
2. Cryo-EM structure of cardiac amyloid fibrils from an immunoglobulin light chain AL amyloidosis patient.
Swuec P; Lavatelli F; Tasaki M; Paissoni C; Rognoni P; Maritan M; Brambilla F; Milani P; Mauri P; Camilloni C; Palladini G; Merlini G; Ricagno S; Bolognesi M
Nat Commun; 2019 Mar; 10(1):1269. PubMed ID: 30894521
[TBL] [Abstract][Full Text] [Related]
3. The CDR1 and Other Regions of Immunoglobulin Light Chains are Hot Spots for Amyloid Aggregation.
Ruiz-Zamora RA; Guillaumé S; Al-Hilaly YK; Al-Garawi Z; Rodríguez-Alvarez FJ; Zavala-Padilla G; Pérez-Carreón JI; Rodríguez-Ambriz SL; Herrera GA; Becerril-Luján B; Ochoa-Leyva A; Melendez-Zajgla J; Serpell L; Del Pozo-Yauner L
Sci Rep; 2019 Feb; 9(1):3123. PubMed ID: 30816248
[TBL] [Abstract][Full Text] [Related]
4. Fatal amyloid formation in a patient's antibody light chain is caused by a single point mutation.
Kazman P; Vielberg MT; Pulido Cendales MD; Hunziger L; Weber B; Hegenbart U; Zacharias M; Köhler R; Schönland S; Groll M; Buchner J
Elife; 2020 Mar; 9():. PubMed ID: 32151314
[TBL] [Abstract][Full Text] [Related]
5. Seeded fibrils of the germline variant of human λ-III immunoglobulin light chain FOR005 have a similar core as patient fibrils with reduced stability.
Pradhan T; Annamalai K; Sarkar R; Huhn S; Hegenbart U; Schönland S; Fändrich M; Reif B
J Biol Chem; 2020 Dec; 295(52):18474-18484. PubMed ID: 33093170
[TBL] [Abstract][Full Text] [Related]
6. Cryo-EM reveals the steric zipper structure of a light chain-derived amyloid fibril.
Schmidt A; Annamalai K; Schmidt M; Grigorieff N; Fändrich M
Proc Natl Acad Sci U S A; 2016 May; 113(22):6200-5. PubMed ID: 27185936
[TBL] [Abstract][Full Text] [Related]
7. Mass spectrometry characterization of light chain fragmentation sites in cardiac AL amyloidosis: insights into the timing of proteolysis.
Lavatelli F; Mazzini G; Ricagno S; Iavarone F; Rognoni P; Milani P; Nuvolone M; Swuec P; Caminito S; Tasaki M; Chaves-Sanjuan A; Urbani A; Merlini G; Palladini G
J Biol Chem; 2020 Dec; 295(49):16572-16584. PubMed ID: 32952127
[TBL] [Abstract][Full Text] [Related]
8. Truncation of the constant domain drives amyloid formation by immunoglobulin light chains.
Lavatelli F; Natalello A; Marchese L; Ami D; Corazza A; Raimondi S; Mimmi MC; Malinverni S; Mangione PP; Palmer MT; Lampis A; Concardi M; Verona G; Canetti D; Arbustini E; Bellotti V; Giorgetti S
J Biol Chem; 2024 Apr; 300(4):107174. PubMed ID: 38499153
[TBL] [Abstract][Full Text] [Related]
9. Immunoglobulin light chain amyloid aggregation.
Blancas-Mejia LM; Misra P; Dick CJ; Cooper SA; Redhage KR; Bergman MR; Jordan TL; Maar K; Ramirez-Alvarado M
Chem Commun (Camb); 2018 Sep; 54(76):10664-10674. PubMed ID: 30087961
[TBL] [Abstract][Full Text] [Related]
10. The Kinetic Stability of a Full-Length Antibody Light Chain Dimer Determines whether Endoproteolysis Can Release Amyloidogenic Variable Domains.
Morgan GJ; Kelly JW
J Mol Biol; 2016 Oct; 428(21):4280-4297. PubMed ID: 27569045
[TBL] [Abstract][Full Text] [Related]
11. Systemic Amyloidosis Due to Clonal Plasma Cell Diseases.
Bianchi G; Kumar S
Hematol Oncol Clin North Am; 2020 Dec; 34(6):1009-1026. PubMed ID: 33099420
[TBL] [Abstract][Full Text] [Related]
12. Cryo-EM structure of a light chain-derived amyloid fibril from a patient with systemic AL amyloidosis.
Radamaker L; Lin YH; Annamalai K; Huhn S; Hegenbart U; Schönland SO; Fritz G; Schmidt M; Fändrich M
Nat Commun; 2019 Mar; 10(1):1103. PubMed ID: 30894526
[TBL] [Abstract][Full Text] [Related]
13. Cryo-EM reveals structural breaks in a patient-derived amyloid fibril from systemic AL amyloidosis.
Radamaker L; Baur J; Huhn S; Haupt C; Hegenbart U; Schönland S; Bansal A; Schmidt M; Fändrich M
Nat Commun; 2021 Feb; 12(1):875. PubMed ID: 33558536
[TBL] [Abstract][Full Text] [Related]
14. The amyloid fibrils of the constant domain of immunoglobulin light chain.
Yamamoto K; Yagi H; Lee YH; Kardos J; Hagihara Y; Naiki H; Goto Y
FEBS Lett; 2010 Aug; 584(15):3348-53. PubMed ID: 20580354
[TBL] [Abstract][Full Text] [Related]
15. The Process of Amyloid Formation due to Monoclonal Immunoglobulins.
Morgan GJ; Wall JS
Hematol Oncol Clin North Am; 2020 Dec; 34(6):1041-1054. PubMed ID: 33099422
[TBL] [Abstract][Full Text] [Related]
16. Barriers to Small Molecule Drug Discovery for Systemic Amyloidosis.
Morgan GJ
Molecules; 2021 Jun; 26(12):. PubMed ID: 34208058
[TBL] [Abstract][Full Text] [Related]
17. Decreased amyloidogenicity caused by mutational modulation of surface properties of the immunoglobulin light chain BRE variable domain.
Kobayashi Y; Tsutsumi H; Abe T; Ikeda K; Tashiro Y; Unzai S; Kamikubo H; Kataoka M; Hiroaki H; Hamada D
Biochemistry; 2014 Aug; 53(31):5162-73. PubMed ID: 25062800
[TBL] [Abstract][Full Text] [Related]
18. Differential recruitment efficacy of patient-derived amyloidogenic and myeloma light chain proteins by synthetic fibrils-A metric for predicting amyloid propensity.
Martin EB; Williams A; Wooliver C; Heidel RE; Adams S; Dunlap J; Ramirez-Alvarado M; Blancas-Mejia LM; Lands RH; Kennel SJ; Wall JS
PLoS One; 2017; 12(3):e0174152. PubMed ID: 28350808
[TBL] [Abstract][Full Text] [Related]
19. Differences in Protein Concentration Dependence for Nucleation and Elongation in Light Chain Amyloid Formation.
Blancas-Mejía LM; Misra P; Ramirez-Alvarado M
Biochemistry; 2017 Feb; 56(5):757-766. PubMed ID: 28074646
[TBL] [Abstract][Full Text] [Related]
20. Mechanistic insights into the aggregation pathway of the patient-derived immunoglobulin light chain variable domain protein FOR005.
Pradhan T; Sarkar R; Meighen-Berger KM; Feige MJ; Zacharias M; Reif B
Nat Commun; 2023 Jun; 14(1):3755. PubMed ID: 37353525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
